"LymPro has completed two Phase 1 clinical studies in over 80 patients, showing 98% sensitivity and 96% specificity for Alzheimer's disease diagnosis."

http://www.fiercemedicaldevices.com/press-rel...c-blood-te

If these are in-line with the numbers that Gerald will release this week the share price will hit the .40-.50 range. Global media will be all over LymPro.

Stay tuned for news.

"The trend is your friend but the science will make you rich."

Twitter: @AmarantusBio .... 10,000+ followers.


p.s. Buckle up!!!